HUMAN CANCER BIOLOGY

Activation of PI3K Signaling in Merkel Cell Carcinoma
Valentina Nardi, Younghel Song, Juan A. Santamaria-Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Byan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, and Dora Dias-Santagata

Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases

HDLC of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer Metastasis
Bing Pan, Hui Ren, Yubin He, Xiaofeng Lv, Yijing Ma, Jang Li, Li Huang, Baoqi Yu, Jian Kong, Chenguang Niu, Youyi Zhang, Wen-bing Sun, and Lemin Zheng

Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promotor Hypermethylation Correlates with Improved Survival
Evgenia Gubanova, Brandee Brown, Sergei V. Ivanov, Thomas Helleday, Gordon B. Mills, Wendell G. Yarbrough, and Natalia Issaeva

CANCER THERAPY: PRECLINICAL

Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb
Takeshi Miyazaki, Yang Pan, Kaushal Joshi, Deepi Purohit, Bin Hu, Haibide Demir, Sarmistha Mazumder, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, and Ichiro Nakano
SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer
Won Gu Kim, Celine J. Guigon, Laura Fozzatti, Jeong Won Park, Changxue Lu, Mark C. Willingham, and Sheue-yann Cheng

Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma
Yang Xu, Venugopal Chenma, Chaoxin Hu, Hai-Xiang Sun, Mehtab Khan, Haibo Bai, Xin-Rong Yang, Qing-Feng Zhu, Yun-Fan Sun, Anirban Maitra, Jia Fan, and Robert A. Anders

IMAGING, DIAGNOSIS, PROGNOSIS

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
Cathy C. Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpit, Cory L. Painter, Qin Zhang, Patrick B. Lappin, Tim Nichols, Maruja E. Lira, Timothy Affolter, Neeta R. Fahey, Carleen Cullinane, Mary Spilker, Kenneth Zasadny, Peter O'Brien, Dana Buckman, Anthony Wong, and James G. Christensen

Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture
Juliette Thariat, Marie-Christine Etienne-Grimaldii, Dominique Gralli, Rémi-Jean Bensadounii, Anne Caye, Frédérique Penault-Llorcaii, Laurence Veracini, Mireille Francoual, Jean-Louis Formento, Olivier Dassonville, Dominique De Raucourt, Lionel Geoffroisi, Philippe Giraud, Séverine Racadot, Sylvain Morinière, Gérard Milanii, and Ellen Van Obberghen-Schilling

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Markus Riester, Jennifer M. Taylor, Andrew Feifer, Theresa Koppie, Jonathan E. Rosenberg, Robert J. Downey, Bernard H. Bochner, and Franziska Michor

Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability
Aimee M. Crago, Nicholas D. Socci, Penelope DeCarolis, Rachael O’Connor, Barry S. Taylor, Li-Xuan Qin, Cristina R. Antonescu, and Samuel Singer

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Hatem A. Azim Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiropouli, and Sherene Loi

Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Timothy R. Donahue, Linh M. Tran, Reginald Hill, Yunfeng Li, Anne Kovochich, Joseph H. Calvopina, Sanjeet G. Patel, Nanping Wu, Anreas Hindoyan, James J. Farrell, Xinmin Li, David W. Dawson, and Hong Wu

Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of 1,6-Branched Oligosaccharides as a Marker of Tumor Progression
Tobias Lange, Sebastian Ulrich, Imke Müller, Michael F. Nentwich, Katrin Stübke, Susanne Feldhaus, Christine Knes, Olaf J.C. Hellwinkel, Robert L. Vessella, Claudia Abramjuk, Mario Anders, Jennifer Schröder-Schwarz, Thorsten Schlomm, Hartwig Huland, Guido Sauter, and Udo Schumacher

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
CANCER THERAPY: CLINICAL

1386 Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, and Richard A. Scolyer
See commentary p. 1192

1395 Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres, Sven de Vos, Brad L. Pohlmans, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrer W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, and Kristen N. Ganjoo

1404 Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
David S. Yoo, John P. Kirkpatrick, Oma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Dunphy, Neal E. Ready, and David M. Brizel

1415 Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

1426 Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Kimberly Noonan, Lakshmi Radhakrishan, Anna Ferguson, Amy Emerling, Marcela F. Pasetti, Carol A. Huff, and Ivan Borrello

1435 A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

1447 CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
Keisuke Aoe, Vishwa Jeet Amatya, Nobukazu Fujimoto, Kei Ohnuma, Osamu Hosono, Akio Hiraki, Masanori Fujii, Taketo Yamada, Nam H. Dang, Yukio Takeda, Kouki Inai, Takumi Kishimoto, and Chikako Morimoto

1457 Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor, Mohammed Kashani-Sabet, Maria Garrido, Steven J. O’Day, Omid Hamid, and Boris C. Bastian

1464 Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
Julie K. Schwarz, Jacqueline E. Payton, Ramachandran Rashmi, Tao Xiang, Yunhe Jia, Phyllis Huettner, Buck E. Rogers, Qin Yang, Mark Watson, Janet S. Rader, and Perry W. Grigsby

1472 Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

CORRECTIONS

1483 Correction: Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

1484 Correction: Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
ABOUT THE COVER

Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.